Study of an experimental drug to treat B-Cell Non-Hodgkin Lymphoma

What we are studying

The purpose of this study is to find the highest dose of CPI-613 that can be given in combination with the drug Bendamustine plus Rituximab for individuals with B-cell Non-Hodgkin Lymphoma without causing severe side effects. Bendamustine and Rituximab are not investigational drugs and have both been approved by the FDA for the treatment of Non-Hodgkin Lymphoma and Hodgkin Lymphoma. In addition, this study will also test the safety and effectiveness of CPI-613 when given in combination with Bendamustine and Rituximab.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Diagnosis of B-Cell Non-Hodgkin Lymphoma
  • Have not been previously treated with Bendamustine for Lymphoma

What is involved

  • Multiple four-week cycles of treatment with CPI-613 and Bendamustine with Rituximab



Contact Information

Study Coordinator
Jennifer Thomas

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.